Houston, Texas 77030


The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab to participants with cancers that have failed to respond to or are known to be insensitive to T cell checkpoint inhibiting antibodies.


For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant - IO therapy resistant or insensitive tumors - Have at least 1 (intramuscular treatment group) or 2 (intratumoral treatment group) tumor lesions accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 Exclusion Criteria: - Primary central nervous system malignancy - Participants with other active malignancy requiring concurrent intervention - Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply.



Primary Contact:

Recruiting sites have contact information. contact the sites directly.If there is no contact information.
Phone: Please email:
Email: Clinical.Trials@bms.com

Backup Contact:

First line of the email MUST contain NCT # and Site #

Location Contact:

Houston, Texas 77030
United States

Filip Janku, Site 0002
Phone: 713-745-4297

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.